U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
| | | | | |

U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

On Dec. 20, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved BRAFTOVI® (encorafenib)…

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
| | | | |

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B

On Dec. 20, 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Alhemo®…

Trichuriasis in Human Patients from Côte d’Ivoire Caused by Novel Species resistant to Albendazole/Ivermectin Combination Treatment
| | | | | | |

Trichuriasis in Human Patients from Côte d’Ivoire Caused by Novel Species resistant to Albendazole/Ivermectin Combination Treatment

On Dec. 18, 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported a study with patient…

Massachusetts General Hospital Received Transformational Gift of $100 Million from Herb Chambers to Revolutionize Cancer Care for Patients and Families
| | | | | |

Massachusetts General Hospital Received Transformational Gift of $100 Million from Herb Chambers to Revolutionize Cancer Care for Patients and Families

On Dec. 11, 2024, Massachusetts General Hospital (MGH), founding member of the Mass General Brigham healthcare system, announced…